Smallpox Treatments: Are Monkeypox Or Mousepox Acceptable Substitutes For Studying The Virus?
This article was originally published in The Pink Sheet Daily
Executive Summary
Smallpox has been eradicated for more than 30 years, but FDA isn't sure whether sponsors studying treatments in animals in case terrorists deliberately infected people can use substitute pathogens under the “Animal Rule.” The Antiviral Drugs Advisory Committee will weigh in on the issue.
You may also be interested in...
SIGA’s Smallpox Drug Tecovirimat Looks Primed For Smooth US FDA Panel Review
Although not tested in smallpox animal models, tecovirimat demonstrated efficacy in surrogate orthopoxvirus disease models in non-human primates and rabbits, FDA says; SIGA seeks approval under the 'Animal Rule' for a broad population of adult and pediatric patients, but agency notes drug's safety has not been clinically tested in children and other vulnerable populations.
Smallpox Discovery Prompts FDA Action Plan; Move To White Oak Unchanged
FDA scientist’s discovery of decades-old vials of smallpox at lab on NIH campus are a reminder of the unsettled debate on whether governments should keep smallpox stock to aid development of antivirals.
Monkeys To Men: “Animal Rule” Study Of Cipro In Plague Gets Advisory Committee
NIH studied the antibiotic known for its efficacy against anthrax as a treatment for pneumonic plague in African Green Monkeys because clinical trials cannot be conducted in human beings.